References
- [APA] American Psychiatric Association2000Diagnostic and Statistical Manual of Mental Disorders4th Ed Text Revision (DSM-IV-TR)WashingtonAPA4726
- AouizerateBGuehlDCunyE2005Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorderNeuropsychiatr Dis Treat12314318568072
- BaldwinDSAjelK2007Role of pregabalin in the treatment of generalized anxiety disorderNeuropsychiatr Dis Treat3185191
- BaldwinDSAndersonIMNuttDJ2005Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol195679616272179
- BaldwinDSPolkinghornC2005Evidence-based pharmacotherapy of generalized anxiety disorderInt J Neuropsychopharmacol829330215576000
- [CADTGI] Canadian Anxiety Disorders Treatment Guidelines Intiative2007Canad J Psychiatry
- GreenbergPSisitskyTKesslerR1999The economic burden of anxiety disorders in the 1990sJ Clin Psychiatry604273510453795
- IronsJ2005Fluvoxamine in the treatment of anxiety disordersNeuropsychiatr Dis Treat12899918568110
- KatzmanMAJacobsL2007Venlafaxine in the treatment of panic disorderNeuropsychiatr Dis Treat35967
- KesslerRMcGonagleKZhaoS1994Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States. Results from the national comorbidity surveyArch Gen Psychiatry518198279933
- LewinABStorchEAGeffkenER2006A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatmentsNeuropsychiatr Dis Treat22131
- LiebRBeckerEAltamuraC2005The epidemiology of generalized anxiety disorder in EuropeEur Neuropsychopharmacol154455215951160
- StrawnJRGeraciotiTD2007Pregabalin treatment of generalized anxiety disorderNeuropsychiatr Dis Treat3237243